BRAIN Biotech AG Deep Dive: Key Takeaways

In this exclusive deep dive, Michael Schneiders, CFO of Brain Biotech AG, takes on the seven most frequently asked questions from institutional investors — offering clarity, conviction, and a forward-looking view on everything from AI-driven enzyme discovery to U.S. expansion, M&A, and the commercial pipeline within the BioIncubator portfolio.

Let’s unpack the key investor topics that matter most to understanding Brain Biotech’s current strategy and its long-term value-creation potential.

1. What are Enzymes, and Why Are They So Attractive?

Enzymes are natural proteins that catalyze biochemical reactions, and Brain Biotech focuses on microbial enzymes with industrial and human applications. Why does this matter to investors? Because enzymes offer low-energy, biodegradable, and sustainable alternatives to chemical synthesis — making them key tools in the green industrial transformation.

The global enzyme market stands at €6 billion, growing at mid-single-digit rates with strong margins. Consumers prefer natural enzyme-based solutions, especially in food, nutrition, and life sciences. Brain, with its unique position and strategic focus, is well-positioned to lead this trend.

2. What Sets Brain Biotech Apart from Other Industrial Biotech Firms?

Michael Schneiders emphasizes Brain’s end-to-end platform—from discovery and AI-assisted enzyme design, to development, fermentation, and production. Few players can offer the full value chain. This integrated model serves three verticals:

Products

Proprietary enzymes for food & life science.

CDMO

Contract manufacturing for biopharma clients.

CRO

Custom research in enzyme innovation.

This makes Brain not just a supplier, but a strategic co-developer with its clients — increasing stickiness, value creation, and margin expansion.

3. How Is AI Revolutionizing Enzyme Discovery at Brain?

Brain’s AI and machine learning platforms are now central to its enzyme innovation engine. Their proprietary platform, “MetXtra,” enables the discovery and synthetic design of novel enzymes, with 99% of the sequences unique to public databases.

With bioinformatics, machine learning, and CRISPR gene editing, Brain is accelerating timelines from idea to prototype, cutting costs, and driving customer success. Their goal: design enzymes that don’t yet exist in nature—customized for client needs.

This digital-first approach is transforming Brain into a tech-enabled biotech innovator—and investors are taking notice.

4. What Are Brain’s Medium-Term Growth Targets, and What Role Does M&A Play?

Brain’s mid-term goal is to double enzyme segment sales through high-single-digit to low-double-digit organic growth. The addressable market for their core activities is approximately €2 billion — and with only €50 million in sales today, there’s massive upside.

Brain also aims to lift its adjusted EBITDA margin from 10% to 15%, unlocking operational leverage as scale increases.

While organic growth is the priority, Brain remains opportunistic on M&A—with a successful track record including Biocatalysts, RareTech, and AnalytiCon Discovery. One more medium-sized acquisition (à la Biocatalysts) is planned within the next 5 years. ..

▶️ Other videos: 

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/ 

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/nvestor-relations-financial-results/ 

ESG Presentation: https://seat11a.com/investor-relations-esg/ 

T&C 

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.